权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bioinspired Multiplexed Ultrasensitive Biosensing

仿生多重超灵敏生物传感

基本信息

批准号：
EP/Z000130/1
负责人：
Molly Stevens
金额：
$ 276.88万
依托单位：
University of Oxford
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2024
资助国家：
英国
起止时间：
2024 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FZ000130%2F1
关键词：
Bioinspired Multiplexed Ultrasensitive Biosensing

项目摘要

Next generation disease detection requires transformative biosensing technologies that are robust, highly sensitive, based on multiple biomarkers, and deployable at the point of care. In bioSense, I propose to meet these needs by pursuing a research programme that simultaneously detects multiple biomarkers ('multiplexed') with extremely high sensitivity ('ultrasensitive'), and develops these multiplexed ultrasensitive diagnostic platforms into point of care devices that have the potential to integrate into online care pathways and enable a patient-centric digital twin. The transformative technological platforms take inspiration from biology to usher in a new era of disease diagnosis. bioSense pursues this ambitious aim through a three-pronged work programme: First, bioSense couples my seminal advances in catalytic nanoparticle technology together with leading-edge developments in gene editing to develop a diagnostic device for the simultaneous detection of noncoding RNA and proteins, a technology I term multiD. Second, bioSense pioneers technology for ultrasensitive detection of nucleic acid patterns, termed NEXTDx. Enhancing multiD and NEXTDx is the development of new catalytic nanoparticles, and underpinning state of the art methodologies including novel imaging technologies developed in-house, hierarchical characterization from atom-level upward, atomistic and coarse-grained computational modelling, and cutting-edge data science approaches that together enable fundamental scientific discoveries and translational outcomes. Collectively, bioSense unlocks the potential of ultrasensitive biosensing for broad clinical and societal impact.

下一代疾病检测需要变革性的生物传感技术，这些技术是强大的，高度敏感的，基于多种生物标志物，并可在护理点部署。在bioSense中，我建议通过追求一项研究计划来满足这些需求，该研究计划可以同时检测具有极高灵敏度（“超灵敏度”）的多种生物标志物（“多重”），并将这些多重超灵敏诊断平台开发成有潜力整合到在线护理路径中的护理点设备，并实现以患者为中心的数字孪生。这些变革性的技术平台从生物学中汲取灵感，开创了疾病诊断的新时代。bioSense通过三管齐下的工作计划来实现这一雄心勃勃的目标：首先，bioSense将我在催化纳米颗粒技术方面的开创性进展与基因编辑方面的前沿发展结合起来，开发出一种用于同时检测非编码RNA和蛋白质的诊断设备，我称之为“多D”技术。其次，bioSense开创了超灵敏检测核酸模式的技术，称为NEXTDx。增强multiD和NEXTDx是开发新的催化纳米颗粒，并支持最先进的方法，包括内部开发的新型成像技术，从原子级向上的分层表征，原子和粗粒度的计算建模，以及尖端的数据科学方法，这些方法共同实现了基础科学发现和转化成果。总的来说，bioSense释放了超灵敏生物传感的潜力，以产生广泛的临床和社会影响。